Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease

Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase

(2018) Ari Zimran et al.   BLOOD CELLS MOLECULES AND DISEASES

Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease

(2016) Ari Zimran et al.   AMERICAN JOURNAL OF HEMATOLOGY

Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

(2016) Gregory M. Pastores et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease

(2016) Ari Zimran et al.   BLOOD CELLS MOLECULES AND DISEASES

Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease

(2015) Ari Zimran et al.   BLOOD CELLS MOLECULES AND DISEASES

Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease

(2015) Richat Abbas et al.   PLoS One

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase

(2014) Gregory M. Pastores et al.   BLOOD CELLS MOLECULES AND DISEASES

Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems

(2013) Yoram Tekoah et al.   BIOSCIENCE REPORTS

First plant-made biologic approved

(2012) Jeffrey L Fox   NATURE BIOTECHNOLOGY

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

(2011) A. Zimran et al.   BLOOD

Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults

(2010) Pramod K. Mistry et al.   BLOOD CELLS MOLECULES AND DISEASES

Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model

(2010) Luc Bracoud et al.   BLOOD CELLS MOLECULES AND DISEASES

Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease

(2009) Carla E.M. Hollak et al.   BLOOD CELLS MOLECULES AND DISEASES